News | September 10, 2024
Briefs: Wanbury and Bafna Pharmaceuticals
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
Subscribe To Our Newsletter & Stay Updated
